Villere ST Denis J & Co. LLC Raises Stock Holdings in CollPlant Biotechnologies Ltd. (NASDAQ:CLGN)

Villere ST Denis J & Co. LLC increased its holdings in shares of CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) by 24.4% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 484,867 shares of the company’s stock after purchasing an additional 95,000 shares during the quarter. Villere ST Denis J & Co. LLC owned approximately 4.23% of CollPlant Biotechnologies worth $2,407,000 at the end of the most recent reporting period.

Separately, Pinnacle Associates Ltd. grew its position in shares of CollPlant Biotechnologies by 6.4% during the second quarter. Pinnacle Associates Ltd. now owns 564,360 shares of the company’s stock worth $2,805,000 after purchasing an additional 33,905 shares in the last quarter. Hedge funds and other institutional investors own 21.69% of the company’s stock.

Analyst Ratings Changes

Several analysts recently issued reports on the company. EF Hutton Acquisition Co. I upgraded CollPlant Biotechnologies to a “strong-buy” rating in a research report on Monday, August 5th. HC Wainwright reiterated a “buy” rating and set a $11.00 target price on shares of CollPlant Biotechnologies in a research report on Wednesday, August 21st.

CollPlant Biotechnologies Trading Up 4.7 %

Shares of CollPlant Biotechnologies stock opened at $3.97 on Friday. The stock has a 50 day moving average of $4.53 and a 200 day moving average of $5.01. CollPlant Biotechnologies Ltd. has a 12 month low of $3.61 and a 12 month high of $6.99. The firm has a market cap of $45.46 million, a PE ratio of -2.58 and a beta of 0.44.

CollPlant Biotechnologies (NASDAQ:CLGN) last announced its quarterly earnings results on Tuesday, August 20th. The company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.02). CollPlant Biotechnologies had a negative net margin of 2,535.70% and a negative return on equity of 65.98%. The firm had revenue of $0.25 million for the quarter, compared to the consensus estimate of $0.70 million. As a group, equities research analysts forecast that CollPlant Biotechnologies Ltd. will post -1.44 earnings per share for the current fiscal year.

About CollPlant Biotechnologies

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology.